Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract

International Journal of Cancer

Volumn 130, Issue 7, 2012, Pages 1671-1681

  Ottinger, Sabine ^a   Klöppel, Anne ^b   Rausch, Vanessa ^a   Liu, Li ^a   Kallifatidis, Georgios ^a   Gross, Wolfgang ^a   Gebhard, Martha Maria ^a   Brümmer, Franz ^b   Herr, Ingrid ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF STUTTGART   (Germany)

Author keywords

natural anti cancer products; pancreatic cancer; tumor initiating cells

Indexed keywords

ANTINEOPLASTIC AGENT; CRAMBE CRAMBE EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG SCREENING; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SPHEROID CELL; SPONGE (PORIFERA); TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CRAMBE SPONGE; DEOXYCYTIDINE; ENDOTHELIAL CELLS; FEMALE; FIBROBLASTS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 84856359151     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26168     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer. J Clin 2009; 59: 225-49.
2. Reya T, Morrison SJ, Clarke MF, Weissman IL,. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111. (Pubitemid 33041634)
3. Ribacka C, Pesonen S, Hemminki A,. Cancer, stem cells, and oncolytic viruses. Ann Med 2008; 40: 496-505.
4. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM,. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
5. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C,. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323. (Pubitemid 47355323)
6. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ,. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951. (Pubitemid 41713363)
7. Belarbi E, Gomez AC, Chisti Y, Camacho FG, Grima EM,. Producing drugs from marine sponges. Biotech Adv 2003; 21: 585-598. (Pubitemid 37143686)
8. Sipkema D, Franssen MCR, Osinga R, Tramper J, Wijffels RH,. Marine sponges as pharmacy. Marine Biotech 2005; 7: 142-162. (Pubitemid 41187741)
9. Da Frota ML, Jr, Braganhol E, Canedo AD, Klamt F, Apel MA, Mothes B, Lerner C, Battastini AM, Henriques AT, Moreira JC,. Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture. Invest New Drugs 2009; 27: 13-20.
10. Kuo PL, Hsu YL, Kuo YC, Chang CH, Lin CC,. The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction. Anti-Cancer Drugs 2005; 16: 789-795.
11. Li JN, Zhu JX, Melvin WS, Bekaii-Saab TS, Chen CS, Muscarella P,. A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. J Gastrointest Surg 2006; 10: 207-214. (Pubitemid 43187182)
12. Uemura C, Takahashi K, Yamamoto T, Katayama C, Tanaka J, Okumura Y, Hirata Y,. Norhalichondrin A: an antitumor polyether macrolide from a marine sponge. J Am Chem Soc 1985; 107: 4796-4798. (Pubitemid 16244006)
13. Hart JB, Lill RE, Hickford SJH, Blunt JW, Munro MHG,. The halichondrins: chemistry, biology, supply and delivery. Switzerland: Karger, Basel, 2000.
14. Mayer AM, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, McIntosh JM, Newman DJ, Potts BC, Shuster DE,. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci 2010; 31: 255-265.
15. Bagley RG, Roth S, Kurtzberg LS, Rouleau C, Yao M, Crawford J, Krumbholz R, Lovett D, Schmid S, Teicher BA,. Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs. Int J Oncol 2009; 34: 1329-1340.
16. Klöppel A, Pfannkuchen M, Putz A, Proksch P, Brümmer F,. Ex situ cultivation of Aplysina spp. close to in situ conditions: ecological, biochemical and histological aspects. Marine Ecol 2008; 29: 259-272. (Pubitemid 351850086)
17. Brümmer F, Nickel M, Sidri M,. Porifera (Schwämme). In:, Hofrichter R, ed. Das Mittelmeered., vol. B and II/1 Bestimmungsführer. Heidelberg: Spektrum Akademischer Verlag, 2003. 302-381.
18. Klöppel A, Grasse W, Bruemmer F, Morlock GE,. HPTLC coupled with bioluminescence and mass spectrometry for bioactivity-based analysis of secondary metabolites in marine sponges. Jpc 2008; 21: 431-436.
19. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A, Mattern J, Li Z, Kolb A, Moldenhauer G, Altevogt P, Wirth T, et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 2009; 58: 949-963.
20. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Büchler MW, Zöller M, Salnikov A, Herr I,. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 2010; 70: 5004-5013.
21. Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A,. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 2008; 68: 1485-1494. (Pubitemid 351346857)
22. Guzman EA, Johnson JD, Carrier MK, Meyer CI, Pitts TP, Gunasekera SP, Wright AE,. Selective cytotoxic activity of the marine-derived batzelline compounds against pancreatic cancer cell lines. Anticancer Drugs 2009; 20: 149-155.
23. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G,. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 2003; 442: 444-452. (Pubitemid 36718311)
24. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB,. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997; 57: 1758-1768. (Pubitemid 27199671)
25. Moul JW, Friedrichs PA, Lance RS, Theune SM, Chang EH,. Infrequent RAS oncogene mutations in human prostate cancer. Prostate 1992; 20: 327-338.
26. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA, Villette JM, Stower MJ, Maitland NJ,. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002; 52: 253-263.
27. Molinski TF, Dalisay DS, Lievens SL, Saludes JP,. Drug development from marine natural products. Nat Rev Drug Discov 2009; 8: 69-85.
28. Bhakuni DR, D,. Bioactive marine natural products. New Delhi, India: Anamaya Publishers, 2005.
29. Blunt JW, Copp BR, Hu WP, Munro MH, Northcote PT, Prinsep MR,. Marine natural products. Nat Prod Rep 2009; 26: 170-244.
30. Proksch P, Ebel R, Edrada RA, Wray V, Steube K,. Bioactive natural products from marine invertebrates and associated fungi. Prog Mol Subcell Biol 2003; 37: 117-142.
31. Proksch PMW,. Frontiers in marine Biotechnology. Horizon Bioscience, 2006.
32. Schwartsmann G, Brondani da Rocha A, Berlinck RG, Jimeno J,. Marine organisms as a source of new anticancer agents. Lancet Oncol 2001; 2: 221-225. (Pubitemid 33585934)
33. Talpir R, Benayahu Y, Kashman Y, Pannell L, Schleyer M,. Hemiasterlin and geodiamolide TA: two new cytotoxic peptides from the marine sponge Hemiasterella minor (Kirkpatrick). Tetrahedron Lett 1994; 44: 53-56.
34. Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 2003; 63: 1838-1845. (Pubitemid 36460846)
35. Hadaschik BA, Ettinger S, Sowery RD, Zoubeidi A, Andersen RJ, Roberge M, Gleave ME,. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. Int J Cancer 2008; 122: 2368-2376. (Pubitemid 351542344)
36. Hirata Y, Uemura D,. Halichondrins-antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986; 58: 701-710. (Pubitemid 16557441)
37. Berlinck RGS, Braekman JC, Daloze D,. Polycyclic guanidine alkaloids from the marine sponge Crambe crambe and Ca2+ channel blocker activity of carmbescidine 816. J Natural Prod 1993; 56: 1007-1015. (Pubitemid 23222200)
38. Uriz MJ, Beccero MA, Tur JM, Turon X,. Location of toxicity within the Mediterranean sponge Crambe crambe. Marine Biol 1996; 124: 583-590. (Pubitemid 26315411)
39. Aron ZD, Pietraszkiewicz H, Overman LE, Valeriote F, Cuevas C,. Synthesis and anticancer activity of side chain analogs of the crambesdidin alkaloids. Bioorg Med Chem Lett 2004; 14: 3445-3449. (Pubitemid 38737144)
40. Aoki S, Kong D, Matsui K, Kobayashi M,. Erythroid differentiation in K562 chronic myelogenous cells induced by Crambescidin 800, a pentacyclic guanidine alkaloid. Anticancer Res 2004; 24: 2325-2330. (Pubitemid 39166313)
41. Garcia Camacho F, Chileh T, Ceron Garcia MC, Sanchez Miron A, Belarbi EH, Contreras Gomez A, Molina Grima E,. Sustained growth of explants from mediterranean sponge crambe crambe cultured in vitro with enriched RPMI 1640. Biotechnol Prog 2006; 22: 781-790. (Pubitemid 43877446)